Adenocarcinoma, Mucinous clinical trials
The registry lists 31 studies for Adenocarcinoma, Mucinous across more than 10 countries. 10 are recruiting or about to start. 9 of them are mainly about Adenocarcinoma, Mucinous (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13. Counting its narrower condition Pseudomyxoma Peritonei too: 63 studies, 23 open.
Get an email when these change. Save the Adenocarcinoma, Mucinous studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
M.D. Anderson Cancer Center (5) · Gynecologic Oncology Group (3) · Royal Marsden NHS Foundation Trust (3) · National Cancer Institute (NCI) (3) · Seagen Inc. (1) · Incyte Corporation (1) · University of California, Irvine (1) · Guangdong Provincial People's Hospital (1)
What is being tested here
Drugs under test in Adenocarcinoma, Mucinous studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Paclitaxel | 1 | 1 | 2 |
| Ivonescimab | 1 | 0 | 1 |
| Samuraciclib | 1 | 0 | 1 |
| Atezolizumab | 0 | 0 | 2 |
| Bevacizumab | 0 | 1 | 2 |
| Nivolumab | 0 | 0 | 2 |
| Ipilimumab | 0 | 0 | 1 |
| Oxaliplatin | 0 | 0 | 1 |
| Gemcitabine | 0 | 1 | 1 |
| Cobimetinib | 0 | 0 | 1 |
Drug classes tested here Immune checkpoint inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- Jan 2027Molecular Profiling for Risk Stratification in Appendiceal Cancer · City of Hope Medical Center
- Apr 2027A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma · M.D. Anderson Cancer Center
- Sep 2027Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · M.D. Anderson Cancer Center
Who these studies take
Of the 8 Adenocarcinoma, Mucinous studies recruiting now, 7 (88%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (13%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (13%) | 1 (13%) |
| 18 | 8 (100%) | 8 (100%) |
| 30 | 8 (100%) | 8 (100%) |
| 40 | 8 (100%) | 8 (100%) |
| 50 | 8 (100%) | 8 (100%) |
| 65 | 8 (100%) | 8 (100%) |
| 75 | 8 (100%) | 8 (100%) |
| 85 | 7 (88%) | 7 (88%) |
Across all 31 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 6% take children; 26% are for women only and 0% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 31 of 31. search them.
- TLR9 Immunotherapy for Peritoneal CarcinomatosisRecruitingNCT07658196Phase 11 country
- Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)RecruitingNCT07795749Phase 21 country
- A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)Not yet recruitingNCT07753824Phase 21 country
- The Appendix Cancer PMP Research Foundation Natural History Study/Patient RegistryRecruitingNCT077693461 country
- A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal AdenocarcinomaRecruitingNCT06207305Phase 1/21 country
- Molecular Profiling for Risk Stratification in Appendiceal CancerRecruitingNCT075872681 country
- Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic CancerNot yet recruitingNCT07665684Phase 1/21 country
- A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal AdenocarcinomaRecruitingNCT05947838Not applicable1 country
- Genetics of Appendix Cancer StudyRecruitingNCT057344301 country
- Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant TumorsRecruitingNCT06182644Not applicable1 country
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic AgentsActive, not recruitingNCT04739800Phase 22 countries
- A Study to Investigate APL-5125 in Adults With Advanced Solid TumorsCompletedNCT06399757Phase 11 country
- Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsActive, not recruitingNCT03074513Phase 21 country
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 22 countries
- A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid TumorsTerminatedNCT05949632Phase 1/21 country
- METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by OxaliplatinActive, not recruitingNCT05504252Phase 21 country
- Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT00565851Phase 33 countries
- Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsCompletedNCT03108131Phase 21 country
- A Study of SGN-STNV in Advanced Solid TumorsTerminatedNCT04665921Phase 16 countries
- Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological CancersCompletedNCT02020707Phase 11 country
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial CancerStatus unknownNCT00492778Phase 22 countries
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsTerminatedNCT03693846Phase 21 country
- Phase I Trial HIPEC With Nal-irinotecanCompletedNCT04088786Phase 11 country
- BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma PeritoneiStatus unknownNCT03976973Phase 2
- The Role of Hypoxia as a Selective Pressure for TP53 MutationsTerminatedNCT034660341 country
- Low Rectal Cancer Study (MERCURY II)Status unknownNCT020059653 countries
- Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 WeeksStatus unknownNCT01037049Phase 24 countries
- Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) TrialStatus unknownNCT019959421 country
- Dalantercept in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01642082Phase 21 country
- Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00888173Phase 21 country
- Nintedanib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01225887Phase 21 country